Manual therapy, prescribed exercises or both vs placebo
Proportion of withdrawals · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
778 questions · 809 findings · 116 reviews
No studies found 205 · 25.3%GRADE not reported 111 · 13.7%Very low 225 · 27.8%Low 155 · 19.2%Moderate 85 · 10.5%High 28 · 3.5%
Manual therapy, prescribed exercises or both vs placebo
Proportion with adverse events · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Manual therapy, prescribed exercises or both vs placebo
Proportion with a serious adverse event · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Manual therapy, prescribed exercises or both vs no intervention or minimal intervention
PainScale: VAS (0 to 10, 0 is no pain) · lateral elbow pain
1 finding from 1 review
- no estimate extracted12 studies · 1023 participantsLow
Manual therapy, prescribed exercises or both vs no intervention or minimal intervention
DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain
1 finding from 1 review
- no estimate extracted10 studies · 732 participantsLow
Summary of findings table ‐ Pseudophakia vs aphakia
Visual acuity · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsVery low
Summary of findings table ‐ Pseudophakia vs aphakia
Visual axis opacification · children younger than two years of age with bilateral congenital cataracts
It is very uncertain whether summary of findings table ‐ Pseudophakia changes visual axis opacification compared with aphakia (very low certainty).
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyRR 1.29 [0.23, 7.13]1 study · 54 participantsVery low
Summary of findings table ‐ Pseudophakia vs aphakia
Amblyopia ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Pseudophakia vs aphakia
Glaucoma at 5 years · children younger than two years of age with bilateral congenital cataracts
It is very uncertain whether summary of findings table ‐ Pseudophakia changes glaucoma at 5 years compared with aphakia (very low certainty).
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyRR 0.86 [0.24, 3.1]1 study · 54 participantsVery low
Summary of findings table ‐ Pseudophakia vs aphakia
Retinal detachment ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Pseudophakia vs aphakia
Reoperation rate ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Pseudophakia vs aphakia
Adverse events · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
- Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsVery low
Botulinum toxin vs placebo
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection showed no clear difference in participant‐reported improvement in sialorrhea in the short term… compared with placebo (low certainty).
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyRR 3 [0.81, 11.08]1 study · 18 participantsLow
Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 participantsVery low
Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo
Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 participantsModerate
Scopolamine (hyoscine) patches vs placebo
Participant‐reported improvement in sialorrhea in the short term · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extracted8 participantsVery low
Scopolamine (hyoscine) patches vs placebo
Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extracted8 participantsVery low
Scopolamine (hyoscine) patches vs placebo
Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
The review found no eligible studies for this question.
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Scopolamine (hyoscine) patches vs placebo
Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes onlyno estimate extracted10 participantsVery low